Table 4.

First and second line therapies for chronic HBV infection recommendations.

	WHO 2024	ALEH 2011	PAHO 2015	AALSD 2018	Brazil 2023	Uruguay 2022	Argentina 2021	Chile 2021	Mexico 2021	Peru 2018	Colombia 2016
First line therapy	TDF or entecavir TAF in persons with osteoporosis or impaired kidney function	TDF, entecavir or PEG-IFN	TDF or entecavir; PLWH should have c-ART with TDF or TAF associated with 3 TC or emtricitabine	TDF, TAF, entecavir or PEG-IFN	TDF	TDF, TAF or entecavir	TDF, TAF or entecavir; PLWH should have c-ART with TDF or TAF associated with 3 TC or emtricitabine	TDF, TAF or entecavir	TDF, TAF or entecavir	TDF	TDF or entecavir
Second line therapy	TDF + 3 TC or emtricitabine (if no access to TDF monotherapy)	adefovir, telvibudina and emtricitabine	adefovir	3 TC, adefovir, telvibudina	entecavir, TAF (if contraindication to TDF and entecavir)	3 TC, emtricitabine, PEG-IFN	Not described	3 TC, PEG-IFN	Not described	entecavir	3 TC, adefovir or telbivudine

AASLD, American Association for the Study of Liver Diseases; ALEH, Asociación Latinoamericana para el Estudio del Hígado; c-ART, combined antiretroviral therapy; PAHO, Pan American Health Organization; PEG-IFN, peg-interferon; PLWH, people living with HIV; TAF, tenofovir alafenamide; TDF, Tenofovir disoproxil fumarate; WHO, World Health Organization. For links to guidelines see Supplementary Table S1.